Blueprint boosts Ayvakit peak sales estimate to $2B as key rare disease expansion accelerates

With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion.

The Massachusetts biotech unveiled the new target Thursday along with its latest earnings results, which showed that Ayvakit brought in $71 million sales in the fourth quarter. The haul marked a 31% sequential growth and beat Wall Street’s consensus by 8%.